A network meta-analysis of therapeutic and prophylactic management of vasospasm on aneurysmal subarachnoid hemorrhage outcomes
DiscussionIn the modern era of subarachnoid hemorrhage, all strategies targeting vasospasm failed to decrease mortality. Cilostazol should be confirmed as a treatment to improve neurological outcomes. The link between vasospasm and neurological outcome appears questionable.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=116073, identifier: PROSPERO CRD42018116073. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - August 17, 2023 Category: Neurology Source Type: research
Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study
AbstractAneurysmal subarachnoid hemorrhage (aSAH) may lead to cerebral vasospasm, significantly associated with morbidity and mortality. In double-blind, placebo-controlled phase 3 studies, clazosentan reduces cerebral vasospasm-related morbidity and all-cause mortality in patients with aSAH. There are no reports about the clinical efficacy of clazosentan combination therapy with some other drugs. Initially, we explored the efficacy of clazosentan combination therapy with cilostazol, statin, and antiepileptic drugs. Subsequently, we assessed the add-on effect of fasudil to clazosentan combination therapy for aSAH patients....
Source: Neurosurgical Review - August 9, 2023 Category: Neurosurgery Source Type: research
Impact of cilostazol on prevention of late failure of autologous vein grafts
CONCLUSIONS: Cilostazol improved the mid-term outcomes after infrainguinal autologous vein bypass.PMID:37545147 | DOI:10.1177/17085381231192730 (Source: Vascular)
Source: Vascular - August 7, 2023 Category: Surgery Authors: Shinsuke Mii Atsushi Guntani Sosei Kuma Masaru Ishida Sho Yamashita Kiyoshi Tanaka Jin Okazaki Source Type: research
Impact of cilostazol on prevention of late failure of autologous vein grafts
CONCLUSIONS: Cilostazol improved the mid-term outcomes after infrainguinal autologous vein bypass.PMID:37545147 | DOI:10.1177/17085381231192730 (Source: Vascular)
Source: Vascular - August 7, 2023 Category: Surgery Authors: Shinsuke Mii Atsushi Guntani Sosei Kuma Masaru Ishida Sho Yamashita Kiyoshi Tanaka Jin Okazaki Source Type: research
E-118 Thromboembolic events during endovascular coiling for unruptured intracranial aneurysms: clinical significance of platelet reactivity unit and adjunctive cilostazol
ConclusionEven though there is a presumed anti-thromboembolic effect for clopidogrel resistance in other literature, the clinical efficacy of adjustment of additional cilostazol for endovascular coiling of unruptured aneurysms may be limited due to the unspecified cutoff value of the PRU assay for evaluating the resistance.Disclosures J. Ahn: None. J. Park: None. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 30, 2023 Category: Neurosurgery Authors: Ahn, J., Park, J. Tags: SNIS 20th annual meeting electronic poster abstracts Source Type: research
Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases
CONCLUSION: This study has confirmed using big data, that EPZ, the optical isomer and racemic form of omeprazole, has the beneficial characteristics of being less sensitive to CYP, as was intended by its design.PMID:37482254 | DOI:10.1016/j.taap.2023.116632 (Source: Toxicology and Applied Pharmacology)
Source: Toxicology and Applied Pharmacology - July 23, 2023 Category: Toxicology Authors: Mami Neishi Hirofumi Hamano Takahiro Niimura Masaya Denda Kenta Yagi Koji Miyata Tsung-Jen Lin Tsukasa Higashionna Mitsuhiro Goda Yoshito Zamami Keisuke Ishizawa Hideki Nawa Source Type: research
Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases
CONCLUSION: This study has confirmed using big data, that EPZ, the optical isomer and racemic form of omeprazole, has the beneficial characteristics of being less sensitive to CYP, as was intended by its design.PMID:37482254 | DOI:10.1016/j.taap.2023.116632 (Source: Toxicology and Applied Pharmacology)
Source: Toxicology and Applied Pharmacology - July 23, 2023 Category: Toxicology Authors: Mami Neishi Hirofumi Hamano Takahiro Niimura Masaya Denda Kenta Yagi Koji Miyata Tsung-Jen Lin Tsukasa Higashionna Mitsuhiro Goda Yoshito Zamami Keisuke Ishizawa Hideki Nawa Source Type: research
The Role of Platelets in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics
Prostaglandins Other Lipid Mediat. 2023 Jul 19:106766. doi: 10.1016/j.prostaglandins.2023.106766. Online ahead of print.ABSTRACTPlatelets are one of the key mediators in thrombosis as well as in the progression of many diseases. An increase in platelet activation and a decrease in platelet count is associated with a plethora of liver diseases. In non-alcoholic fatty liver disease (NAFLD), platelets are highly activated and participate in the disease progression by enhancing the pro-thrombotic and pro-inflammatory state. Some altered platelet parameters such as mean platelet volume, plateletcrits, and platelet distribution ...
Source: Atherosclerosis - July 21, 2023 Category: Cardiology Authors: Malladi Navya Md Jahangir Alam Subir K Maulik Sanjay K Banerjee Source Type: research
Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke
ConclusionsThis real-world study suggests that cilostazol is effective and safe for noncardioembolic ischemic stroke and may be associated with better effectiveness in hypertensive patients compared to clopidogrel. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - June 13, 2023 Category: Drugs & Pharmacology Source Type: research
Isosorbide Mononitrate and Cilostazol in Patients With Symptomatic Cerebral Small Vessel Disease
This randomized clinical trial examines treatment outcomes with isosorbide mononitrate and cilostazol in patients with symptomatic cerebral small vessel disease. (Source: JAMA Neurology)
Source: JAMA Neurology - May 24, 2023 Category: Neurology Source Type: research
The Use and Impact of Cilostazol on Patients Undergoing Peripheral Vascular Interventions
This study assesses the use and impact of cilostazol on patients undergoing PVI for peripheral arterial disease (PAD). (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - May 23, 2023 Category: Surgery Authors: Dana Alameddine, Fachreza Aryo Damara, Paula Pinto-Rodriguez, Joshua J. Huttler, Martin Slade, Isibor Arhuidese, Edouard Aboian, Cassius Iyad Ochoa Chaar Tags: Interactive Poster Session Source Type: research
Effect of Cilostazol in Platelet Inhibition in Patients With Peripheral Artery Disease
Cilostazol is a quinolone derivate known mainly for its vasodilatory properties and its use in the treatment of intermittent claudication in patients with peripheral artery disease. Cilostazol is a phosphodiesterase III inhibitor that increases cAMP in platelets and blood vessels, increasing protein kinase A levels which is related to platelet inhibition. The emergence of viscoelastic assays, such as thromboelastography with platelet mapping, have been utilized to identify prothrombotic states and may provide insight into a patient's microvascular coagulation profile. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - May 23, 2023 Category: Surgery Authors: Sasha P. Suarez Ferreira, Ryan Hall, Monica Majumdar, Guillaume Goudot, Samuel Jessula, Zach M. Feldman, Tiffany Bellomo, Ivy Lee, Lois Owolabi, Amanda Kirshkaln-Leahy, Kathryn Nuzzolo, Anahita Dua Tags: Poster Competition Source Type: research
Postoperative Benefits of Cilostazol on Patients Undergoing Intervention for Chronic Limb Ischemia
Although prior studies have shown the short-term benefits of cilostazol on claudicant patients who underwent iliac or femoropopliteal revascularization procedures, the literature on patients with chronic limb ischemia (CLI) is limited. Recent molecular analysis suggests that the possible cardiovascular benefits of cilostazol are mediated through a nitric oxide pathway. As such, we hypothesized that cilostazol use in patients undergoing intervention for CLI would have reduced major adverse limb events, reinterventions, and improved long-term survival. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - May 23, 2023 Category: Surgery Authors: Jose Antonio Munoz, Alexandra A. Sansosti, Yaagnik Kosuri, Danielle Bajakian, Nicholas Morrissey, Karan Garg, Jeffrey J. Siracuse, Jessica Ding, Abhishek Rao, Katharina Horn, Priya B. Patel, Thomas F.X. O'Donnell, Virendra I. Patel Tags: Poster Competition Source Type: research
Multicenter, retrospective registry of isolated atherosclerotic popliteal arteries treated with endovascular revascularization
This study aimed to investigate the efficacy of endovascular therapy (EVT) using the newer devices for IAPLs. This retrospective multicenter registry analyzed patients with lower extremity artery disease having IAPLs who underwent EVT using the newer devices between 2018 and 2021. The primary outcome was primary patency 1 year after EVT. A total of 392 consecutive patients undergoing EVT for IAPLs were enrolled. The Kaplan–Meier analysis showed that the primary patency and the freedom from target lesion revascularization were 80.9% and 87.8% 1 year after EVT, respectively. The multivariate Cox proportional hazar ds re...
Source: Heart and Vessels - May 23, 2023 Category: Cardiology Source Type: research
Effect of Cilostazol on Preventing Paclitaxel ‐Induced Neuropathy in Patients with Breast Cancer: A Randomized Controlled Trial
ConclusionAdjunctive use of cilostazol may be considered as a novel option that might reduce the incidence of paclitaxel-induced peripheral neuropathy and improve the patients ’ QoL. Future larger clinical trials are warranted to confirm these findings. (Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy)
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 18, 2023 Category: Drugs & Pharmacology Authors: Esraa A. Haroun,
Noha O. Mansour,
Ahmed Eltantawy,
Mohamed E. E. Shams Tags: RESEARCH ARTICLE Source Type: research
